



ELEKTA AND NUCLETRON COMBINE FORCES TO MARKET LEADING SOFTWARE

Press Release

Stockholm, Sweden, May 18, 2009

Elekta and Nucletron have reached an agreement to market and license Elekta's software system MOSAIQ®. Nucletron's existing Oncentra® Visir and Oncentra® Information Management customers will be offered a high-quality solution with excellent future prospects of continued innovation from the world's largest supplier of oncology software.

The business arrangement was reached in response to Nucletron's recent decision to cease development, sales, and marketing of its Oncentra Visir and Oncentra Information Management product lines. Nucletron will focus efforts on innovations in brachytherapy and treatment planning for external beam.

MOSAIQ is an Oncology Information Management system that features an image-enabled electronic medical record fully integrated with comprehensive administrative management functionality that provides workflow automation designed specifically for the oncology specialty. Supporting multi-vendor, multi-disciplinary, and multi-site organizations, it unites diverse systems and ensures that all information about a cancer treatment is easily accessible throughout the entire treatment process.

"We look forward to working with Nucletron to deploy MOSAIQ throughout their installed base with minimal interruption to the cancer centers' normal workflow routine. This will afford us a deeper understanding of the specific needs of an increasingly diverse oncology user base, which we will use to create more optimal informatics and workflow solutions for oncology professionals practicing in a variety of settings" says Jay Hoey, Executive Vice President of Elekta Software Systems.

"The decision to phase-out Oncentra Visir and Oncentra Information Management will enable us to further increase our efforts to innovate within the areas of brachytherapy and treatment planning for external beam. With this decision we enforce our mission and vision and refocus our strengths to live up to the promise of improving patient care," says Jos Lamers, Chief Executive Officer of Nucletron B.V.

For further information, please contact:

Lena Schattauer, Investor Relations, Elekta AB

Tel: +46 8 587 257 22, +46 70 595 51 00, e-mail: lena.schattauer@elekta.com

Danielle Davis, Media Contact, Nucletron B.V.

Tel: +1 443-834-6725, e-mail: ddavis@rosecomm.com



About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTA. For more information about Elekta, please visit www.elekta.com.

About Nucletron

Nucletron is a global leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams – reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians. For more information about Nucletron, please visit www.nucletron.com.